Clinical trials
Prostatitis clinical trials
Below are recruiting prostatitis clinical trials, each written for real people, not researchers. We’re tracking 1,358 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05869682RecruitingPhase 2
Bright light therapy for fatigue and depression in prostate cancer
This Phase 2 study tests whether a “bright white light” intervention can reduce cancer-related fatigue and depression in people with advanced prostate cancer receiving hormone-based treatment. If it works, it could improve day-to-day well-being while you’re on standard cancer therapies.
Duarte, CaliforniaAges 60 years+ - NCT05574244Recruiting
Partial vs complete prostate surgery to preserve ejaculation
This trial compares two surgical approaches for men with benign prostate enlargement (BPH): one that aims to preserve ejaculation and one that removes more tissue. It looks at how well you recover urinary function and sexual outcomes after surgery.
Aix-en-ProvenceAges 40 years+ - NCT05398302RecruitingPhase 1
Biopsies during prostate cancer treatment to study resistance
This early study uses image-guided biopsies (small tissue samples taken with imaging) to learn why metastatic prostate cancer may stop responding to PSMA radioligand therapy. The results may help doctors understand resistance and improve future treatments.
Los Angeles, CaliforniaAges Any age - NCT04734730RecruitingPhase 2
Talazoparib plus hormone therapy for metastatic prostate cancer
This trial tests whether talazoparib added to standard hormone therapy (ADT), along with abiraterone, can better control metastatic prostate cancer that hasn’t progressed despite starting hormone treatment. It may help people live longer and delay cancer worsening.
Duarte, CaliforniaAges 18 years+ - NCT03354416Recruiting
Imaging study of prostate cancer risk and treatment outcomes
This study looks at how prostate cancer shows up on scans and how those imaging findings relate to treatment and outcomes. It may help doctors better predict risk and guide care, especially for people with higher risk or early or suspected prostate cancer.
Bethesda, MarylandAges 18 years+ - NCT00923221Recruiting
Donate blood for people with prostate cancer
This trial collects blood samples from adults with prostate cancer. It may help researchers learn more about the disease or how treatments work, without directly testing a new drug in the eligibility you provided.
Bethesda, MarylandAges 18 years+ - NCT04084938Recruiting
Clot-blocking treatment versus surgery for enlarged prostate
This trial compares artery embolization (blocking blood flow to the prostate) with standard surgery for urinary symptoms caused by an enlarged prostate. It may help patients who have moderate-to-severe bladder outlet symptoms and are looking for a treatment option when medicine didn’t work (or they don’t want medicine).
OsloAges Any age - NCT06292897Recruiting
Obesity and prostate cancer tissue study
This study looks at how obesity might affect prostate cancer growth. It uses tissue samples to understand the role of certain metabolites in the tumor, which could lead to better treatments.
MilanAges 18 years+ - NCT04694924Recruiting
Prostate cancer patient registry to track experiences
This study builds a database of people with localized or locally advanced prostate cancer to better understand patient-reported outcomes (your experiences and quality-of-life). It may help improve future care by collecting consistent feedback from patients.
Dendermonde, Oost-VlaanderenAges 18 years+ - NCT05352178RecruitingPhase 3
Targeted treatment for few-spread prostate cancer spots
This Phase 3 trial tests whether treating only a small number of prostate cancer metastases can help people with “oligorecurrent” (limited repeat) prostate cancer. It may reduce cancer activity while avoiding broader whole-body treatment for some patients.
LeuvenAges 18 years+ - NCT07790718Recruiting
Exercise program to prevent colorectal cancer after prostate radiation
This study tests whether an exercise program can help prevent colorectal cancer in men who have had pelvic radiation for prostate cancer. It involves using an iPhone app to track activity and attending exercise sessions.
Duarte, CaliforniaAges 40–80 - NCT07745361RecruitingPhase 2
Study of MRT-2359 with apalutamide for prostate cancer
This trial tests a new oral drug, MRT-2359, combined with apalutamide (a standard hormone therapy) in men with a specific type of prostate cancer that has stopped responding to hormone treatment. The goal is to see if the combination can slow or stop the cancer's growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07710807Recruiting
Comparing two prostate biopsy methods
This trial compares two ways to take a prostate biopsy (through the rectum or through the skin between the scrotum and anus) to see which is more accurate. Men with suspicious MRI findings (PI-RADS 3, 4, or 5) who haven't had prostate cancer before may be eligible.
Ankara, YenimahalleAges 50–75 - NCT07641049RecruitingPhase 1
CAR-NK Cell Therapy for Advanced Prostate Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight advanced prostate cancer that has stopped responding to hormone treatments. The cells are engineered to recognize and attack cancer cells that have specific markers (PSMA and PSCA) on their surface.
Shenzhen, GuangdongAges 18 years+ - NCT07627178Recruiting
Comparing laser treatments for enlarged prostate
This study compares three different surgical laser techniques to treat benign prostate enlargement (BPH) that causes severe urinary symptoms and hasn't improved with medication. The goal is to find which method is safest and works best for large prostates.
Tanta, Gharbia GovernorateAges Any age - NCT06706921RecruitingPhase 4
Predicting treatment success with PET scans in prostate cancer
This study looks at whether a special PET scan can help predict how well a targeted radiation therapy (LuPSMA) works in men with advanced prostate cancer that has spread. You would get several PET scans before and after treatment to see if the scan results can forecast your outcome.
Los Angeles, CaliforniaAges 18 years+ - NCT07557901Enrolling by invitation
Antibiotics to prevent infection after prostate biopsy
This study tests whether taking antibiotics before a prostate biopsy (a needle procedure to check for cancer) reduces infections. You would receive either standard care or a specific antibiotic plan, and researchers will track any infections that develop.
Banská BystricaAges Any age - NCT07516886Recruiting
Early PSA levels after prostate surgery and cancer outcomes
This study looks at how PSA (a blood marker) levels measured shortly after prostate removal surgery can predict whether cancer comes back. Researchers hope this helps doctors identify patients who may need closer monitoring or additional treatment after surgery.
Kaunas, KaunoAges 18 years+ - NCT07483658Recruiting
Salvage pelvic radiotherapy: 20 vs 25 sessions for recurring prostate cancer
This trial compares two schedules of pelvic radiotherapy for men whose prostate cancer has returned after surgery. Both schedules aim to control the cancer with fewer visits for one of them.
Gatineau, QuebecAges 18 years+ - NCT07343349Recruiting
Adding a higher radiation dose to prostate tumors during standard radiotherapy
This trial tests whether giving an extra, focused dose of radiation to the visible tumor inside the prostate can improve results for men with intermediate or high-risk prostate cancer that has not spread. The total treatment is given in 12 or 20 sessions.
AarhusAges 18 years+ - NCT07276438Recruiting
Image-guided radiation therapy for localized prostate cancer
This trial tests a precise radiation technique that adapts to your body's daily changes. It may offer better outcomes for men with prostate cancer that hasn't spread outside the pelvic area.
Los Angeles, CaliforniaAges 18 years+ - NCT07179783RecruitingPhase 2
Sacituzumab Tirumotecan and Tagitanlimab for aggressive prostate cancer
This trial tests a combination of two drugs for men with aggressive or neuroendocrine prostate cancer that has worsened after previous hormone therapy. The goal is to see if the combination can shrink tumors or slow the disease.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07131956Recruiting
Immune biomarkers in prostate cancer brachytherapy
This study looks at immune system markers in men getting brachytherapy (internal radiation) for prostate cancer. It may help us understand how the body responds to this treatment.
Augsburg, BavariaAges 18 years+ - NCT07103018RecruitingPhase 1
Study of KTX-2001 for men with advanced prostate cancer
This trial tests a new drug called KTX-2001, possibly combined with another drug (darolutamide), for men whose prostate cancer has spread and stopped responding to standard hormone treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
San Francisco, CaliforniaAges 18 years+
Hear when a new Prostatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostatitis?
- Yes. Clin2 currently lists 1,358 recruiting prostatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.